Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

FDA Introduces Data Modernization Action Plan

Posted on March 29th, 2021 by in Pharma R&D

One of the frustrations of our Big Data era is that, despite the existence of an ever-growing wealth of valuable data, this data is often stuck in different silos. This lack of accessibility makes it hard to get the most out of data that has the potential to be extremely useful.

(more…)

Elsevier to Work with Heel for Mechanism-based Drug Action Discovery

Posted on January 6th, 2021 by in Pharma R&D

Elsevier, the data analytics business specialized in science and health, and Heel, a pharmaceutical company specialized in developing and manufacturing medicines made from natural ingredients, have recently completed a series of research projects with a focus on improving exploratory preclinical studies.

(more…)

5 Ways RWE is Fueling the Fight Against COVID-19

Posted on June 19th, 2020 by in COVID-19

As we discussed in an earlier blog post, real-world evidence can bring value to every stage of the drug life cycle, from early discovery to post-market. Now, as the worldwide research community continues to battle the COVID-19 pandemic, we are also discovering how real-world data and real-world evidence have something to offer in these efforts as well.

(more…)

How Are Regulatory Agencies Reacting to the Use of Real-World Evidence?

Posted on June 15th, 2020 by in Pharma R&D

As we have discussed here previously, real-world data (RWD) and real-world evidence (RWE) offer many potential benefits in every stage of the drug discovery and development process, continuing on into post-market surveillance. With drug developers and other researchers becoming more interested in using RWD and the RWE that results from analyzing it, regulatory agencies have had to step up and work on producing guidance.

(more…)

  1. 1
  2. 2
  3. 3
  4. 9